Pharmacopsychiatry 2008; 41(4): 134-137
DOI: 10.1055/s-2008-1058106
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Treatment with Clomethiazole is Associated with Lower Rates of Premature Discharge during Alcohol Withdrawal

T. Hillemacher[*] 1 , C. Weinland[*] 1 , A. Heberlein 1 , J. Wilhelm 1 , K. Bayerlein 1 , J. Kornhuber 1 , H. Frieling 1 , S. Bleich 1
  • 1Department of Psychiatry and Psychotherapy, University Hospital Erlangen, Erlangen, Germany
Further Information

Publication History

received 14.06.2007 revised 21.12.2007

accepted 14.01.2008

Publication Date:
23 July 2008 (online)

Abstract

Introduction: Numerous investigations have shown that premature discharge against medical advice from alcohol detoxification treatment is associated with poor outcome. The aim of the present study was to assess the risk of different possible influencing factors.

Patients and Method: 168 in-patients admitted for detoxification treatment were included in the study. All patients were detoxified using clome-thiazole and/or carbamazepine in individual, symptom-triggered dosages. Possible influencing factors were recorded using a standardised interview.

Results: Cox regression revealed a lower risk of premature discharge being significantly asso-ciated with few preceding withdrawals, intoxication at admission and treatment with clomethiazole. Kaplan-Meier survival statistics showed a significantly lower risk only for being treated with clomethiazole (premature discharge until day 7: χ2=25.07; p<0.001; premature discharge until day 14: χ2=5.19; p=0.023). Other included demographic factors like daily intake of ethanol before admission, duration of alcohol dependence, age or smoking status were not associated with the risk of premature discharge.

Discussion: The present findings show that pharmacotherapy with clomethiazole may positively influence the risk of premature discharge. This might be a consequence of the psychoactive properties of the drug which leads to positive reinforcement.

References

  • 1 Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior.  Alcohol Clin Exp Res. 1995;  19 92-99
  • 2 Anton RF, Moak DH, Latham PK. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies.  Arch Gen Psychiatry. 1996;  53 225-231
  • 3 Armenian SH, Chutuape MA, Stitzer ML. Predictors of discharges against medical advice from a short-term hospital detoxification unit.  Drug Alcohol Depend. 1999;  56 1-8
  • 4 Beck NC, Shekim W, Fraps C, Borgmeyer A, Witt A. Prediction of discharges against medical advice from an alcohol and drug misuse treatment program.  J Stud Alcohol. 1983;  44 171-180
  • 5 Bleich S, Carl M, Bayerlein K, Reulbach U, Biermann T, Hillemacher T. et al . Evidence of increased homocysteine levels in alcoholism: The Franconian Alcoholism Research Studies (FARS).  Alcohol Clin Exp Res. 2005;  29 334-336
  • 6 Blondell RD, Amadasu A, Servoss TJ, Smith SJ. Differences among those who complete and fail to complete inpatient detoxification.  J Addict Dis. 2006;  25 95-104
  • 7 Borras L, Timary P de, Constant EL, Huguelet P, Eytan A. Successful treatment of alcohol withdrawal with trazodone.  Pharmacopsychiatry. 2006;  39 232
  • 8 Chang G, Kosten TR. Detoxification. In: Lowinson JH, Ruiz P, Millmann RB, Langrod JG, eds. Substance Abuse: A Comprehensive Textbook. Baltimore: Williams and Wilkins 1997: 377-381
  • 9 Gallimberti L, Spella MR, Soncini CA, Gessa GL. Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence.  Alcohol. 2000;  20 257-262
  • 10 Green AR, Davies EM, Little HJ, Whittington MA, Cross AJ. Action of chlormethiazole in a model of ethanol withdrawal.  Psychopharmacology (Berl). 1990;  102 239-242
  • 11 Green P, Watts D, Poole S, Dhopesh V. Why patients sign out against medical advice (AMA): factors motivating patients to sign out AMA.  Am J Drug Alcohol Abuse. 2004;  30 489-493
  • 12 Hazel M, Cooksey RC, Jones D, Parker G, Neidigh JL, Witherbee B. et al . Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance.  Endocrinology. 2004;  145 2118-2128
  • 13 Hillemacher T, Bayerlein K, Wilhelm J, Bönsch D, Poleo D, Sperling W. et al . Recurrent detoxifications are associated with craving in patients classified as type 1 according to Lesch's typology.  Alcohol Alcohol. 2006;  41 66-69
  • 14 Hwang SW, Li J, Gupta R, Chien V, Martin RE. What happens to patients who leave hospital against medical advice?.  Cmaj. 2003;  168 417-420
  • 15 Kristensen CB, Rasmussen S, Dahl A, Lauritsen B, Lund K. The Withdrawal Syndrome Scale for alcohol and related psychoactive drugs: Total scores for guidelines for treatment with phenobarbital.  Nord Psykiatr Tidsskr. 1986;  40 139-146
  • 16 Lange-Asschenfeldt C, Muller MJ, Szegedi A, Anghelescu I, Klawe C, Wetzel H. Symptom-triggered versus standard chlormethiazole treatment of inpatient alcohol withdrawal: clinical implications from a chart analysis.  Eur Addict Res. 2003;  9 1-7
  • 17 Martinez-Raga J, Marshall EJ, Keaney F, Ball D, Strang J. Unplanned versus planned discharges from in-patient alcohol detoxification: retrospective analysis of 470 first-episode admissions.  Alcohol Alcohol. 2002;  37 277-281
  • 18 Morgan MY. The management of alcohol withdrawal using chlormethiazole.  Alcohol Alcohol. 1995;  30 771-774
  • 19 Schuckit MA. Inpatient and residential approaches to the treatment of alcoholism. In: Mendelson JH, Mello NK, eds. Medical Dia-gnosis and Treatment of Alcoholism. New York: McGraw-Hill 1992: 393-419
  • 20 Soyka M, Schmidt F, Schmidt P. Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence.  Pharmacopsychiatry. 2006;  39 30-34
  • 21 Usala M, Thompson SA, Whiting PJ, Wafford KA. Activity of chlormethiazole at human recombinant GABA(A) and NMDA receptors.  Br J Pharmacol. 2003;  140 1045-1050

1 Both authors contributed equally.

Correspondence

S. BleichMD 

Department of Psychiatry and Psychotherapy

University of Erlangen-Nuremberg

Schwabachanlage 6

91054 Erlangen

Germany

Phone: +49/9131/853 42 62

Fax: +49/9131/853 41 05

Email: stefan.bleich@uk-erlangen.de